Results 1 to 10 of about 2,105 (152)

Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report

Frontiers in Oncology, 2023
We report the case of a 68-year-old man who developed a sigmoidorectal fistula after marked response to enfortumab vedotin for advanced bladder cancer. The patient had undergone radical cystectomy with ileal conduit after neoadjuvant chemotherapy.
Shinji Tamada, Daiki Ikarashi, Naoki Yanagawa, Moe Toyoshima, Kenta Takahashi, Tomohiko Matsuura, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Wataru Obara   +10 more
doaj   +1 more source

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Case Reports in Oncology, 2023
Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that is recently being used in the management of patients with urothelial carcinoma. The common adverse events include rashes, peripheral neuropathy, and hyperglycemia. Only a few cases of
Takamasa Homma, Kuniaki Tanaka, Naoya Takeda, Yu Okada, Shota Torii, Hideki Esaki, Takashi Sakakibara, Norio Takimoto   +7 more
doaj   +1 more source

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report

Kidney Medicine, 2023
Enfortumab vedotin is a novel breakthrough therapy that received accelerated US Food and Drug Administration approval in 2019 for the treatment of metastatic urothelial carcinoma in patients who have failed other lines of treatment.
Francis Atemnkeng, Fatima Aguilar, Sanjeev Gupta, Savneek Chugh, Michael Klein   +4 more
doaj   +1 more source

A case of marked rectal stenosis due to Douglas’ pouch metastasis of renal pelvic carcinoma successfully treated with salvage enfortumab vedotin: correlation between serum KL‐6 levels and tumor response

IJU Case Reports, 2023
Introduction We report a rare case of marked rectal stenosis due to Douglas' pouch metastasis of renal pelvic urothelial carcinoma successfully treated with enfortumab vedotin.
Jun Akatsuka, Go Kimura, Akifumi Katsu, Hiroya Hasegawa, Hikaru Mikami, Masato Yanagi, Yuki Endo, Hayato Takeda, Yuka Toyama, Yukihiro Kondo   +9 more
doaj   +1 more source

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Frontiers in Oncology, 2021
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade.
Paul V. Viscuse, Mario L. Marques-Piubelli, Meghan M. Heberton, Edwin Roger Parra, Amishi Y. Shah, Arlene Siefker-Radtke, Jianjun Gao, Sangeeta Goswami, Doina Ivan, Jonathan L. Curry, Jonathan L. Curry, Matthew T. Campbell   +11 more
doaj   +1 more source

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma

IJU Case Reports, 2023
Introduction Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%).
Yuji Mimura, Aya Kobayashi, Haruhiko Utazu, Yuki Matsumoto, Hiroya Mizusawa   +4 more
doaj   +1 more source

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin

International Medical Case Reports Journal, 2021
Alexa Thibodeau, Nambi Nallasamy Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USACorrespondence: Nambi NallasamyDepartment of Ophthalmology and Visual Sciences, W.K.
Thibodeau A, Nallasamy N
doaj  

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin

Cancer Management and Research, 2023
Muhammad Ashir Shafique, Abdul Haseeb, Mohammad Arham Siddiq, Abdullah Mussarat, Hussain Sohail Rangwala, Muhammad Saqlain Mustafa Department of Medicine, Jinnah Sindh Medical University, Karachi, PakistanCorrespondence: Muhammad Ashir Shafique ...
Shafique MA, Haseeb A, Siddiq MA, Mussarat A, Rangwala HS, Mustafa MS   +5 more
doaj  

The successful management of SJS/TEN secondary to enfortumab vedotin therapy

Current Problems in Cancer: Case Reports, 2022
A 47-year-old female with poorly differentiated carcinoma of urothelial origin on pembrolizumab, presented to the hospital with fever, dysuria, pruritus, diffuse erythema, and skin desquamation 11 days after starting immunotherapy with enfortumab vedotin
Rhea Singh, BS, Fnu Nutan, MD
doaj   +1 more source

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer

Frontiers in Oncology
Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, and pembrolizumab, an immune checkpoint inhibitor,
Blaine Brower, Asia McCoy, Hiba Ahmad, Cheryl Eitman, I. Alex Bowman, Jennifer Rembisz, Matthew I. Milowsky, Matthew I. Milowsky   +7 more
doaj   +1 more source